Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17067734 | 0.95 | ATM (0.54) | ATMALDH1A1SMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL17067735 | 0.92 | ATM (0.57) | ATMALDH1A1SMN1; SMN2L3MBTL1CYP2A6 | |
| SCHEMBL31705854 | 0.85 | ATM (0.50) | ATMALDH1A1CYP2A6CYP11B2CYP11B1 | |
| SCHEMBL31705294 | 0.85 | ATM (0.50) | ATMALDH1A1CYP2A6CYP11B2CYP11B1 | |
| SCHEMBL31704913 | 0.85 | ATM (0.50) | ATMALDH1A1CYP2A6CYP11B2CYP11B1 | |
| SCHEMBL8619431 | 0.82 | HSD17B10 (0.50) | ATMALDH1A1SMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL28280560 | 0.82 | ATM (0.53) | ATMALDH1A1SMN1; SMN2L3MBTL1CYP2A6 | |
| SCHEMBL31706262 | 0.81 | ATM (0.46) | ATMALDH1A1SMN1; SMN2NPSR1CYP11B2 | |
| SCHEMBL4128802 | 0.81 | ATM (0.46) | ATMALDH1A1SMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL10068936 | 0.80 | HSD17B10 (0.51) | ATMALDH1A1SMN1; SMN2NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | ATM 3952/4885ALDH1A1 3559/4885SMN1; SMN2 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.